PharmGen Science Inc
PharmGen Science, Inc. engages in the research and development, production, and sale of pharmaceutical products in South Korea. It provides prescription drugs, OTC drugs, diagnostic test kits, health and general foods, and cosmetics, as well as shampoo, conditioner, and hair oil products under the neomcell brand name. The company was formerly known as Wooridul Pharmaceutical Limited and changed i… Read more
Market Cap & Net Worth: PharmGen Science Inc (004720)
PharmGen Science Inc (KO:004720) has a market capitalization of $56.27 Million (₩82.39 Billion) as of March 18, 2026. Listed on the KO stock exchange, this Korea-based company holds position #22906 globally and #1199 in its home market, demonstrating a 1.35% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PharmGen Science Inc's stock price ₩3760.00 by its total outstanding shares 21912592 (21.91 Million).
PharmGen Science Inc Market Cap History: 2015 to 2026
PharmGen Science Inc's market capitalization history from 2015 to 2026. Data shows change from $100.27 Million to $56.27 Million (-6.06% CAGR).
PharmGen Science Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PharmGen Science Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
PharmGen Science Inc's market cap is 0.00 times its annual revenue
0.84x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.02x
PharmGen Science Inc's market cap is 0.02 times its annual earnings
11.15x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $100.27 Million | $60.41 Billion | $2.07 Billion | 0.00x | 0.05x |
| 2016 | $258.16 Million | $71.55 Billion | $3.45 Billion | 0.00x | 0.07x |
| 2017 | $171.36 Million | $79.89 Billion | $4.32 Billion | 0.00x | 0.04x |
| 2018 | $110.75 Million | $89.10 Billion | $4.47 Billion | 0.00x | 0.02x |
| 2019 | $95.33 Million | $95.14 Billion | $301.98 Million | 0.00x | 0.32x |
| 2020 | $169.11 Million | $96.61 Billion | $9.22 Billion | 0.00x | 0.02x |
| 2021 | $157.14 Million | $109.87 Billion | $32.47 Billion | 0.00x | 0.00x |
| 2022 | $99.97 Million | $150.93 Billion | $70.06 Billion | 0.00x | 0.00x |
| 2023 | $92.79 Million | $166.78 Billion | $6.09 Billion | 0.00x | 0.02x |
| 2024 | $61.21 Million | $171.29 Billion | $2.79 Billion | 0.00x | 0.02x |
Competitor Companies of 004720 by Market Capitalization
Companies near PharmGen Science Inc in the global market cap rankings as of March 18, 2026.
Key companies related to PharmGen Science Inc by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #15 globally with a market cap of $883.37 Billion USD.
- Johnson & Johnson (NYSE:JNJ): Ranked #18 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #29 globally with a market cap of $390.88 Billion USD.
- AstraZeneca PLC (NASDAQ:AZN): Ranked #46 globally with a market cap of $296.35 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #15 | Eli Lilly and Company | NYSE:LLY | $883.37 Billion | $989.12 |
| #18 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $243.19 |
| #29 | AbbVie Inc | NYSE:ABBV | $390.88 Billion | $221.45 |
| #46 | AstraZeneca PLC | NASDAQ:AZN | $296.35 Billion | $192.01 |
PharmGen Science Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, PharmGen Science Inc's market cap moved from $100.27 Million to $ 56.27 Million, with a yearly change of -6.06%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩56.27 Million | -9.51% |
| 2025 | ₩62.18 Million | +1.59% |
| 2024 | ₩61.21 Million | -34.03% |
| 2023 | ₩92.79 Million | -7.19% |
| 2022 | ₩99.97 Million | -36.38% |
| 2021 | ₩157.14 Million | -7.08% |
| 2020 | ₩169.11 Million | +77.39% |
| 2019 | ₩95.33 Million | -13.92% |
| 2018 | ₩110.75 Million | -35.37% |
| 2017 | ₩171.36 Million | -33.62% |
| 2016 | ₩258.16 Million | +157.46% |
| 2015 | ₩100.27 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of PharmGen Science Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $56.27 Million USD |
| MoneyControl | $56.27 Million USD |
| MarketWatch | $56.27 Million USD |
| marketcap.company | $56.27 Million USD |
| Reuters | $56.27 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.